Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

22.26 -0.56 (-2.45%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

27 28 29 30 31 32 33 34 Next >

Why Sarepta Therapeutics Shares Dropped More Than 16% This Week ↗

November 04, 2021

The biotech stock fell a little more than $72 since its close last Friday.

Via The Motley Fool

Analyst Ratings For Sarepta Therapeutics ↗

November 04, 2021

Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:...

Via Benzinga

Sarepta Therapeutics (SRPT) Q3 2021 Earnings Call Transcript ↗

November 04, 2021

SRPT earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering ↗

November 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...

Via Benzinga

Topics Retirement

Expert Ratings For Sarepta Therapeutics ↗

October 15, 2021

Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:

Via Benzinga

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗

July 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...

Via Benzinga

Earnings Scheduled For November 3, 2021 ↗

November 03, 2021

Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion....

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

Is This Beaten Down Biotech a Bad News Buy? ↗

October 20, 2021

It has lagged the market over the last five years but with a promising gene therapy, is Sarepta worth another look?

Via The Motley Fool

Why Sarepta Therapeutics Fell 14.7% This Week ↗

October 14, 2021

Investors were unimpressed by the company's clinical and financial news.

Via The Motley Fool

50 Biggest Movers From Yesterday ↗

October 14, 2021

Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating...

Via Benzinga

Why Sarepta Therapeutics Tumbled Today ↗

October 13, 2021

Investors weren't wowed by a company update, or by news of a fresh stock issue.

Via The Motley Fool

40 Stocks Moving In Wednesday's Mid-Day Session ↗

October 13, 2021

Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 13, 2021

Gainers Revance Therapeutics (NASDAQ:RVNC) stock moved upwards by 17.79% to $24.09 during Wednesday's pre-market session. The company's market cap stands at $1.7...

Via Benzinga

The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal ↗

October 13, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the...

Via Benzinga

A Peek Into The Markets: US Stock Futures Gain Ahead Of CPI, Fed Minutes ↗

October 13, 2021

Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade after the Dow Jones dropped more than 100 points in the previous session. Investors are...

Via Benzinga

Topics Economy Stocks

5 Stocks To Watch For October 13, 2021 ↗

October 13, 2021

Some of the stocks that may grab investor focus today are: Wall Street expects JPMorgan Chase & Co. (NYSE: JPM) to report quarterly earnings at $3.00 per share on revenue...

Via Benzinga

What 5 Analyst Ratings Have To Say About Sarepta Therapeutics ↗

October 12, 2021

Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:...

Via Benzinga

Sarepta's Duchenne Gene Therapy Shows Sustained Functional Improvements ↗

October 11, 2021

Sarepta Therapeutics Inc (NASDAQ: SRPT) shared new analyses and functional data from its SRP-9001 development program and the details of Study SRP-9001-301 (EMBARK...

Via Benzinga

Sarepta, Codiak Nix Exosome Therapy Development Pact ↗

October 08, 2021

Sarepta Therapeutics Inc (NASDAQ: SRPT) notified Codiak BioSciences Inc (NASDAQ: CDAK) that it would terminate the two-year Research License and Option...

Via Benzinga

The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight ↗

September 19, 2021

Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2021 ↗

September 15, 2021

Upgrades For Alcoa Corp (NYSE:

Via Benzinga

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs ↗

October 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...

Via Benzinga

5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal ↗

September 14, 2021

Gene therapy is set to become one of the most vital spaces with high prospects in the biotech sector.

Via Talk Markets

The Latest Barron's Picks And Pans Include General Electric, Netflix, Reddit And More ↗

September 04, 2021

This weekend's Barron's reveals what market strategists recommend for a stock market that likely will struggle this fall. Other featured articles discuss biotech stocks...

Via Benzinga

'Fast Money Halftime Report' Picks For August 24 ↗

August 24, 2021

On CNBC's "Fast Money Halftime Report," Stephanie Link said Aptiv PLC (NYSE: APTV) is worthy of a buy. Jon Najarian bought Sarepta Therapeutics Inc (NASDAQ: SRPT) on...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2021 ↗

August 05, 2021

Upgrades Stephens & Co. upgraded the previous rating for Roku Inc (NASDAQ:

Via Benzinga

99 Biggest Movers From Yesterday ↗

August 06, 2021

Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a...

Via Benzinga

Sarepta Therapeutics (SRPT) Q2 2021 Earnings Call Transcript ↗

August 05, 2021

SRPT earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Earnings Scheduled For August 4, 2021 ↗

August 04, 2021

Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter. • Vericel (NASDAQ:VCEL) is expected to...

Via Benzinga

< Previous 1 2

...

27 28 29 30 31 32 33 34 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

All News about Sarepta Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today